Viole nce in th e psychiatric setting ma y be pe r pet rated by patie nts with a va r ie ty of diagnoses includi n g characte r d isorde r s, episodic d yscontrol syndromes, and drug o r a lco hol into xication . The vio lent be havio r o f ag gressive psychotic patients is typi call y the most bi zarr e , unpred ictable , and th e least respo nsive to intervention with neuroleptics or lithium carbonate. Carbama zepine , an estab lished anticonvulsant, has ac h ieved growing prominence as an adj u nc t ive measure in treatment o f th e vio le nt psych o tic . This paper will re vie w th e lit erature and su m m a r ize th e posited p ha r m aco log ica l mech a nisms, reported sid e e ffects, a nd clinical experience wit h carbamazepine in controll ing th e sym p to ms of vio lence and aggressio n in ps ychosis.
An ticon vul san ts were first used in the treatment of aggr essive psych o tic patients in 1943 (1) . Carbamazepi ne , introduced in 19 6 3 as an anticon vulsant particularly effec tive in temporal lobe e pilepsy, has bee n reported to be useful in treating aggressio n associated wit h psych o sis in patie nts with bipolar affective di sorder, schizoaffec tive di sorde r , a nd sch izophren ia with and without EEG a b no r malit ies . T he first successfu l open clin ical tria ls in patients with bipo lar d iso rde r were co nd ucted in Japan in t he early 197 0 's. Two groups o f in vestigators d emonstrat ed a nti-ma n ic and slig h t anti-depressive effects in 75 % (2) and 55 %, respectivel y, of th eir patients with bipolar affective disorder, and proph ylactic effects in both manic (7 1%) a nd d epressive (64 %) episodes (3 ,4) , although some patients recei ved combinat ions o f carbamazepine and lith iu m and/or other drugs.
A se r ies of double-blind con trolled trials foll ow ed these stu d ies . Okuma et a l. co m pared chlorpromazin e a nd ca r ba ma zepi ne a nd reported equivalent anti-manic effects (5) . Ball enge r and Post co nd uc ted d ouble-bl ind , placebocontrolled trials of carbamazepine in nine mani c patients, seven of whom had partial to marked therapeutic r esponses (6); a n additio nal pati e n t who had been unresponsive to lithium and other anticonvulsan ts a lso impr oved on carbamazepine (7) . Subsequent published case s a nd open st ud ies reported the efficacy o f ca r bamaze pine combined with lithium carbonate (8) (9) (10) (11) (12) (13) (14) (15) , pa r ticul a rl y in pati ents in whom lithium was less effect ive or who exper ie nced a contin uo us circular or a rapidly cycling co u rse . Post et al. also provid ed case repo rts wh ich suggest th at car bamaze p ine ma y have prophyla cti c e ffec ts (16) . Oku ma e t a l. conducted a
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double-blind controlled trial showing prophylacti c e ffec ts of ca r bamazepine in 60 % and placebo in 22.2% of their patients (V-test, p < 0.10) ( 17) . Kishimoto et at. found some prophylactic effect s of carbamazepine in ma nic and depressive episodes in 75 % of their thirty-two cases, all foll ow ed for at least se ven years; the effects being significantly greater in the group with onset of illness be fore age 20 (p < 0.0 I, Fisher's exact test) (18) . A double-blind controlled st ud y comparing carbamazepine plus haloperidol a nd placebo plus haloperidol in lit h iu m carbonat e-a nd neuroleptic-resistant patients with "excite d psych oses" found a signi ficant imp rovem e n t of sym pto ms including " host ility" and "excitement" in the treatment group ov er th e placebo group (p < .0 3), although both groups improved ( 19) .
There are also r eports of pati ents with sch izoaffective disorder who responded to ca r bamazep ine . Folks, King et at. obse rved impro veme nt in two of three such patients given carbamazepine (14) . Brooks a nd Lessi n re ported the successful carbamazepine treatment o f a m an with sch izoa ffec tive disorder and resi stant lithium-induced nephrogenic diabet es ins ip id us (20) . Kraft, Hass enfeld , a nd Zarr published th e case of a previously treatm en t-re fracto r y patient whose auditor y hallucinations responded to carbamazepine (21) . Despite enc o uraging case reports, to date th ere has been no co ntrolled trial of carbarnazep ine in sch izoaffec tive di sorder.
Carbamazepine ha s been prescribed for schizop hrenics wit h and without ab no r ma l EEG's in whom vio le nt behavior was particularl y problematic. In an open trial, Hakola and Laulumaa treated e ig h t schizoph r en ics wit h co mb inations of carbamazepine and neuroleptics. The e igh t pati en ts all showed EEG abnormalities but had not been diagnosed as epilep tic. Foll o win g the combination treatment, all eight patients showed d ecr ea sed aggressive behavio r , and four of th e eight showed dimin ish ed symptoms o f schizophrenia as well (22) . Luchins had similar results in six schizop h ren ics wit h no rm al EEG's (23) , and Yassa and Dupont reported a similarly-r esp onsive case (24) . Ne p pe conducted a double-blind, randomized study o f car bamazepine in e leven ch ron ic schi zophrenics with EEG abnormalities, e igh t of wh om impro ved wh ile on carbamazepine (p = .03 , Wilcoxon ; p < .005 , ANOV A) (25) . In contrast, Stevens and Bigelow et at. reported two cases of psychosis aggravated by th er apeut ic doses of carbamazepine (26) . In summary, th e available lit erature suggests th at carbamazepine may be a useful adjunctive measure in the treatment of agg r essive or violent psychotic patients, some of whom may ha ve EEG abnormalities. Carbamazepine's apparent effect on both aggressive behavior and psych otic sym ptoms raises qu estions about the compound's mechanism of ac tion . T he only anticonvulsant with a tricyclic structur e , carbamazepine is a polycyclic d rug whose steric structure resembles th at o f chlorpromazine , imiprami ne , and maprotiline. Because its three rings lie in a plane different from th at of the amide group, it resembles other anti convulsants as we ll (27) . Carbama zepine is classified as a neutral lipophilic substance, whi ch enables th e mol ecul e to pa ss eas ily through lipid m embranes and facilitates its transport into th e ce ntra l ner vou s system . Two different metabolic pathways are dis cernible: epoxidatio n of po sit io n 10, 11 by hepatic monooxygenases, and h ydroxylation in one of th e aromatic rings by hepatic oxygenases. Both metabolites undergo subsequent g luc uronide formation. The epoxidation pathway is quantitatively t he more impo r tant one, a nd there is speculation that 10, II-epoxycarbamazepine co n tr ib utes to the drug's an t ie pile p t ic (and possible anti-aggressive) activity (28) . T here is also evidence which suggests that carbamazepine induces ce r ta in en zymes, e .g ., cytochrome P-450 and epoxide hydrase, and may hasten its own d egradatio n . The measured half-life after a single dose (37 hours) is sig n ifica n tly greater th a n the ha lf-life after r epeated doses (28 hours) in multiple trials (28 ) .
Animal st ud ies initially demonstrated carba m azepine's anticonvulsive effects and located its site of action in th e limbic region of the b rai n. Carbamazepine's anti-epileptic properties were most e vid ent in electricall y-ind uced seizures in rats and mice, and somewhat less pronounced in ch emicall y in d uced seizures in these animals. Hypothalamicall y-induced rage in cats was a lso controlled b y ca r ba maze pine, suggesting effectiveness in specific typ es of aggression . In th e cat e pile psy model, electrical stimulation o f va r io us limbic st ructures produced after-discharges recorded in the stimulated structures th emsel ves and interrelated areas. The hippocampal aft er-discharge, possibl y invol ved in psychom otor epilepsy and a particularly useful measure of a n tico nvu lsant efficacy, was shorte ned by ca r bam aze pine at a d ose of 3 mg/kg in ca ts . T he drug had no effect on the Purkinje cells of th e cerebella r co r te x, suggest ing that t he mode of anticonvulsant action of carbamazepine differs fr o m that of diphe nylh yda nto in and diazepam (29) . Studies of th e fighting behavior o f mi ce suggest that carbamazepine in high doses has general anti-aggressive an d anxio lytic effects. Antiparkinsonian and anticholinergic properties also ap pear o n ly at very high doses. Contrary to clinical reports in humans, trad itio nal reserpi ne and amphetam ine antagonism trials in animal s have not d emonstrated a n tidepressant or antipsychotic effects.for carbamazepine. To measure ca r bam azepi ne's possible a n ti-de p r essan t activity, 1,000 mg/kg o f th e drug was ad mi n istered to rodents with reserpine-induced ptosis but produced no antagonistic effect. Similarly, to test for neuroleptic properties, 300 mg/kg of ca r ba mazepine was given to rats with amphetamine-induced ste reotyp y, again without a n tagon ism (29) . These findings have led investigators to focu s on th e limbic syste m-te m poral lo be area as the primary site of carbamazepine 's action and to atte m p t to identify possible neurochemical exp la nat io ns for its psychotropic e fficacy.
Postulating an association between th e high d ensity of op iate receptors in th e limbic system and carbamazepine's mech anism of ac tion , Post et al. measured opioid activity in patients with affecti ve di sorders treat ed with ca r bama zep ine . They reported that th e drug exe r te d no significa nt effect on cerebral spinal fluid (CSF) opioid activity (30), a nd fou nd no sig n ificant association between CSF GABA levels and carbamazepine dose or bl ood le vel of th e drug (31) . They subsequently exam ined th e effec ts of ca r bamazepine on receptors of various major neurotransmitters and o th er su bs ta nces . Data sug-gested t hat, u n like neuro leptics, carbamazepine does not block dopam ine receptors. It did not produce parkinsonian symptoms, tard ive d yskinesia, o r inhibition or suppression of unit firing dopaminergic neuro ns of the su bs ta ntia nigra b y apomorphine; it did produce minimal elevations of prolactin but di d not diminish cocaine-nor amphetamine-induced h yp eracti vity. Be n zodi aze pine receptor antagonists did not affect ca rbamaz epine's a nticon vu lsant ac tivi ty in amygdaloid seizures, suggesting little effect of ca r bam azepine at th e be n zod iazepine receptor as wel l. Carbamazepine failed to inhibit binding at se veral recep to r sites, including muscarinic-cholinergic e H-Q N B), d opami ne e H-spiroperidol), GABA e H-m uscimo l), imipramine , beta-adre nergic e H-D HA), an d op iate e H-na lo xo ne) receptors. H o wev er, di splacement of adenos ine a na logs was demonstrated, indicating effec ts o n th e adenosin e rece pto r , a nd a bl ock ad e of both release a n d reuptake of norepinephrine , whic h ma y be re lat ed to carbamazepine 's apparent efficacy in bipola r illn ess (32) . O th e r documented effects of carbamazepine include d ecreased circ u lat ing T 3 and T 4 , efficacy as a vasopressin agonist, increased urinary fr ee co r t iso l, a nd d ecr eased CS F somatostat in (32) .
Post and hi s group proposed th at ca rbam azepine , through its an ticonvulsa nt properties, ma y represent a new class o f psych otropic agents for t he treatment of affective d ysr egulation , including aggress io n as a sym p to m of a h yperexcited state or limbic seizure (33) . This h ypothesis was based o n Dalby's successful use of carbamazepine in patients with te m pora l lobe e pilepsy a nd mood disorders (34, 35) , carbamazepine's inhibition of exper imenta lly induced kindling in the limbic system (particu la rly amygda loi d se izu res) , a nd Po st an d his co wo r ker s' succe ss in treating affecti vel y di sordered patie nts wit h carbamazepine. In Post's model , th ese su bcor tica l se izu res, wh ich co uld man ifest as behavioral aberrations such as aggression and psych o sis, wo uld no t necessarily produce EEG abnormal ities; kindling co u ld oc cur with either e n viron me nta l o r e nd ogeno us stimuli (36) . H eath 's work with deep brain EEG recordings in e pile p tics and schizophrenics als o provid es so me su pport for Post 's mode l. Heath d escribes sei zure-like acti vit y in th e am ygdala , hippocam pus, an d sep ta l region of e pile p t ics with vio le nt psych otic e p isod es wh ich clo se ly resembled the sp ike and slow-wa ve patterns ob ta ined fr om th e same brain regions in no nep ileptic aggressive psychotic patients and ps ychotic sch izo p hren ics (37) .
A lthough the use of carbamazepine in psychiatric patients is increasing as more data are published, treatment guidelines and side e ffect p r ofiles have not ye t been fully agreed upon. Experimental protocol s have suggested ad m inis tration of car bamaze pine in doses r anging from 200 m g/d to 2 ,000 mg/ d , wit h most recommending initial doses of 200-400 m g/d with gra d ual upward titration to the point of maximum cl inical e fficacy o r d ose-lim iting sid e effects (6) . Post e t al. r eport treatment with 1,600-2,000 m g/ d wit h few side effects (38) . Blood and CSF le vel s of the drug have been shown to bea r no re lat ionship to clinical response when th e drug is used to treat aggressive psych o tic psych iatri c patients, although CSF le vel s o f ca r bamazep ine-10 , ll-e pox id e correlated significantly with clinical response when measured after a month of treatment (38) . Side effects, however, do appear to be related to th e plasm a level in some patients, becoming more intolerable when the se r u m concen tration exceeds 9 ug/ml (38) . The most commonly reported side effects include diplopia , skin rash, fatigue , unsteadiness, transient paresthesias in th e extrem ities, reversible lupus erythematosis syndrome, nystagmus, drowsiness, na usea, vomiting, an d neutropenia (39) . Though decreases in white blood cell co u nts are usually clinically insignificant, there have been ca ses of aplasti c a nem ia (40) and agranulocytosis (4 1) r eported with carbamazepine. Other hematolog ic effects include thrombocytopenia (42) , reticulocytosis (43) , and leukocytosis (44) . Although the incidence of these blood dyscrasias is low, hematologic m o ni tori ng should include a complete blood and platelet count prior to th erapy and weekly co m p le te blood counts for the first month , followed b y mon thl y whi te b lood ce ll counts (40) . If leukopenia develops, the dose of the drug sh o uld be d ecreased and the white cell count monitored biweekly. In the e vent of in fectio n or sev ere leukopenia (WBC less than 3 ,OOO/mm 3 o r neutrophil co un t less than 1,500/ mrn "), carbamazepine should be discontinued (4 1).
There are reports of additional side e ffe cts and so me dru g inte r act io ns involving carbamazepine. Because its ch emical structure is so closely related to tricyclic antidepressants, carbamazepine ma y potentiate t he action of these drugs when they are used in combination (39, 45) . Reiss a nd O 'D onnell report two cases of paradoxical carbamazepine-induced mania in chi ld ren with fami ly histories of affective di sorder (4 6) . Fogelson sugges ts th at ata x ia, confusion, a nd vomiting can occur when ca r bamaze p ine dosage is increased to o abruptly in patients previously unexposed to th e drug, as th e y hav e lo wer cle arance than those who take it regularly (47 ) . At toxic level s, ca r bamazepine is also kno wn to produce encephalopathy (39) or sch izo p h ren ia-like psych o sis (48) in susceptible patients. Kanter et al. described a patient with bipolar disorder wh o was started on carbamazepine and haloperidol a nd d eveloped a n ac u te o rganic b rain synd ro me with low serum lev els of carbamazepine . The syn d rome reso lved with discontinuation of both medications, and the mania was subsequentl y controlled on carbamazepine 200 mg b.i.d. alone. The authors sug ges t th at a central nervous syste m interaction between th e two drugs was respo nsib le for the organic symptoms (49) . Lithium carbonate-carbamazepine co m b ina tions can produce signs of neurotoxicity (50, 51) , despite therapeutic se r u m le vel s of bot h drugs, and th ere is o ne cas e report of an organic brain syn d rome with a lithium carbonate-carbamazepine-haloperidol combination (52 ) . Isoniazid, when given with carbamazepine, produces delirium (53, 54) . There is o ne repo rt of neurotoxicity when carbamazepine was co m b ined with m etoclopramide (55) . hde and Post observed sign ifica nt decreases in se rum so d iu m, ch ori de , and ca lciu m in their patients treated with ca r bama zepine, but th ese cha nges were not correlated with treatment response , although those patients wh o im pro ved on car bamazepine tended to have greate r d epression o f seru m sodium level s. T hey a lso sugge ste d that some " n o nspeci fic" sid e effec ts ma y ac tually be symptoms o f hyponatremia (56) , possibly due to water intoxication, whi ch has also bee n reported (57 ,58) . Finally, carbamazepine administration has so met imes led to h ypoth yroidism with and without elevations of th yroid st im u lating hormone (59 ,32) , as well as to hepatitis (60) .
Although th e Food and Drug Administration ha s not yet app roved the use of carbamazepine in refractory vio le n t ps ychiatri c pati ents, th e lite ratu re suggests that this compound, used alone or in combination with conventional agents, may be beneficial in the treatment of psychoses asso ciat ed wit h bipola r affective disorder, schizoaffective disorder, and schizophrenia . T hrough its anticonvulsant action or another ye t unidentified m echanism , carbamazepine appears to co n tr o l limbic se izu res, which ma y be related to bo th psychosis and aggression. Familiarity with potential sid e effec ts and dru g interactions is necessary as the use of carbamazepine increases. Finally, additional clin ical trials are necessary to further assess the safety and spectrum o f ca r ba mazepine's efficacy.
